This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
by Zacks Equity Research
Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
by Zacks Equity Research
MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.
Will ACADIA Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in ACADIA Pharmaceuticals Inc.
Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
by Zacks Equity Research
Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 13.79% and 0.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Top Healthcare Mutual Funds to Buy in October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make healthcare funds a strong investment option
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars
by Zacks Equity Research
Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.
FDA Confirms Positive Safety Profile of Acadia's Nuplazid
by Zacks Equity Research
Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -13.33% and -1.58%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?
by Zacks Equity Research
On ACADIA's (ACAD) second-quarter 2018 conference call, investor focus will be on the sales figures of its only marketed drug Nuplazid as well as its pipeline progress.
Dopamine and the Weather, Part 2
by Kevin Cook
How technology changes human behavior and social rules, but not human nature and genetics???yet.
ACADIA Posts Narrower than Expected Loss in Q1, Sales Beat
by Zacks Equity Research
ACADIA posted narrower than expected loss in the first quarter of 2018 and sales beat estimates.
Will ACADIA (ACAD) Disappoint Investors This Earnings Season?
by Zacks Equity Research
ACADIA (ACAD) is expected to release first-quarter 2018 results on May 8 and provide updates on its drug, Nuplazid.
Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
ACADIA (ACAD) is expected to provide further update on the progress of Nuplazid when it reports Q4 results on Feb 27.
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
by Zacks Equity Research
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
4 Biotech Stocks Ready to Crush the Market in 2018
by Zacks Equity Research
The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.
Why the Earnings Streak Will Continue for ACADIA Pharmaceuticals (ACAD)
by Zacks Equity Research
ACADIA Pharmaceuticals (ACAD) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.
Minerva Initiates Phase III Study on Schizophrenia Candidate
by Zacks Equity Research
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
by Zacks Equity Research
TherapeuticsMD (TXMD) announces the acceptance of its resubmitted NDA for TX-004HR for treating dyspareunia as Class 2 response. A likely delay in approval drives shares down.
Shire's New Formulation of Oncaspar Gets Approval in Europe
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.